...
首页> 外文期刊>Journal of International Medical Research >Dose Escalation Induces Tolerance to Side-Effects of Erythropoietin in a Patient with Dialysis Anaemia: Case Report
【24h】

Dose Escalation Induces Tolerance to Side-Effects of Erythropoietin in a Patient with Dialysis Anaemia: Case Report

机译:剂量升高诱发对透析性贫血患者促红细胞生成素副作用的耐受性:病例报告

获取原文
           

摘要

A 51-year-old woman began haemodialysis for chronic renal failure in February 1981. Symptomatic anaemia required treatment with recombinant human erythropoietin (rHuEPO) in February 1990 (3000 IU, twice weekly, intravenously). She developed influenza-like symptoms and treatment was withdrawn. In June 1994 rHuEPO was resumed at a very low dose of 100 IU subcutaneously three times weekly, and was increased gradually to 500 IU, without inducing any side-effects. At this dose the haematocrit was maintained at 22.0 – 25.0% and the symptoms of anaemia improved. In patients like ours, with influenza-like symptoms caused by rHuEPO therapy, dose escalation starting from an ultra-low dose may be effective in avoiding side-effects.
机译:一名51岁妇女于1981年2月开始因慢性肾功能衰竭进行血液透析。有症状的贫血需要在1990年2月用重组人促红细胞生成素(rHuEPO)治疗(3000 IU,每周两次,静脉注射)。她出现了类似流感的症状,并取消了治疗。 1994年6月,rHuEPO每周皮下注射3次,剂量非常低,为100 IU,并逐渐增加至500 IU,而没有引起任何副作用。在此剂量下,血细胞比容维持在22.0 – 25.0%,贫血症状得以改善。在像我们这样的患者中,由于rHuEPO治疗引起的流感样症状,从超低剂量开始的剂量递增可能有效避免副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号